Abeona Therapeutics (ABEO) vs Contineum Therapeutics (CTNM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Abeona Therapeutics (ABEO) has outperformed Contineum Therapeutics (CTNM) over the past year, losing 17.7% versus a loss of 39.5%. Contineum Therapeutics is the larger company by market cap ($266.4 million vs $253.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABEO | CTNM |
|---|---|---|
| Share price | $4.43 | $7.08 |
| Market cap | $253.33M | $266.36M |
| 1-day change | -4.73% | -10.38% |
| YTD return | -15.94% | -38.06% |
| 1-year return | -17.66% | -39.49% |
| 5-year return | -79.40% | — |
| EPS (TTM) | $-1.18 | $-1.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $5.82M | — |
| Net income (latest FY) | $71.18M | $-59.98M |
| Gross margin | 73.68% | — |
| Operating margin | -1536.91% | — |
| Net margin | 1223.08% | — |
| 52-week high | $7.65 | $17.79 |
| 52-week low | $4.00 | $6.95 |
| Distance from 52-week high | -42.09% | -60.19% |
| Analyst consensus | none | buy |
| Avg. price target upside | +326.19% | +212.71% |
| Average volume | 1.40M | 732.62K |
| Shares outstanding | 57.18M | 32.96M |
| Employees | 226 | 51 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABEO has outperformed CTNM by 21.8 percentage points over the past year.
About Abeona Therapeutics
ABEO stock →Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa.
Health Care · Biotechnology: Pharmaceutical Preparations · 226 employees
About Contineum Therapeutics
CTNM stock →Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 51 employees
ABEO vs CTNM FAQ
Which is bigger, Abeona Therapeutics or Contineum Therapeutics?
Contineum Therapeutics (CTNM) is larger, with a market capitalization of $266.36M compared with $253.33M for Abeona Therapeutics (ABEO).
Which stock has performed better over the past year, ABEO or CTNM?
ABEO returned -17.66% over the past 12 months, compared with -39.49% for CTNM (price return, excluding dividends). Past performance does not predict future results.
Are Abeona Therapeutics and Contineum Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.